Navigation Links
Rigel Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/1/2011

SOUTH SAN FRANCISCO, Calif., March 1, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2010.

For the fourth quarter of 2010, Rigel reported a net loss of $17.2 million, or $0.33 per share, compared to a net loss of $25.1 million, or $0.48 per share, in the fourth quarter of 2009. Weighted average shares outstanding for the fourth quarter of 2010 and 2009 were 52.2 million and 51.8 million, respectively.

There was no contract revenue reported in the fourth quarter of 2010. Contract revenue in the fourth quarter of 2009 was $750,000, comprised of a milestone payment from Daiichi Sankyo for the designation of the first lead compound related to the ligase oncology collaboration.

Rigel reported total operating expenses of $19.7 million in the fourth quarter of 2010, compared to $25.9 million in the fourth quarter of 2009. The decrease in operating expenses was primarily due to the completion of the transfer of the fostamatinib open label extension study to AstraZeneca AB (AZ) in September 2010.

In the fourth quarter of 2010, Rigel reported other income of approximately $2.4 million related to the Therapeutic Discovery Tax Credit Program (Section 48D of the Internal Revenue Code).  Rigel received cash proceeds of $2.1 million in the fourth quarter of 2010 and will receive the remaining $0.3 million in 2011.

For the twelve months ended December 31, 2010, Rigel reported contract revenue of $125.0 million and net income of $37.9 million, or $0.73 and $0.72 per basic and diluted share, respectively, compared to contract revenue of $750,000 and a net loss of $111.5 million, or $2.73 per basic and diluted share, for the same period of 2009.  The increase in contract revenue was due mainly to the $100.0 million upfront payment received pursuant to the ex
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015 Vermillion, Inc. (Nasdaq: ... focused on gynecologic disease, announced today it will ... the market open on Wednesday, March 25, 2015, ... at 8:30am Eastern. Conference Call & Webcast: ... Eastern/5:30am Pacific Domestic: , 800-753-9057International: , 913-981-5571Conference ID: ...
(Date:3/5/2015)... YORK , March 5, 2015  As ... set of regulations, Ethics & Compliance professionals are ... to a new survey issued today by LRN, ... and education. An overwhelming majority of respondents expressed ... the most important component of E&C training programs ...
(Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3
... Cytotech Labs, a Boston based pharmaceutical company and ... Berg Biosystems and Berg Diagnostics today presented groundbreaking insight ... Otto Warburg.  The Warburg Hypothesis asserts that increased utilization ... by cancer cells in return for evasion of apoptosis, ...
... April 4, 2011 Breckenridge is announcing that it entered ... Salalah, Sultanate of Oman to market Neomycin Sulfate Tablets. Under ... by Oman Pharma, and marketed and distributed by Breckenridge on ... been approved by the U.S. Food and Drug Administration (FDA), ...
Cached Medicine Technology:Cytotech Labs Unravels Hallmark Insight Into Metabolic Control of Cancer, Presents Work at Major AACR Cancer Meeting 2Cytotech Labs Unravels Hallmark Insight Into Metabolic Control of Cancer, Presents Work at Major AACR Cancer Meeting 3Cytotech Labs Unravels Hallmark Insight Into Metabolic Control of Cancer, Presents Work at Major AACR Cancer Meeting 4
(Date:3/5/2015)... Central Nebraska Imaging (CNI) is pleased to ... new logo and optimized website. , CNI’s ... to expert diagnostic imaging, centered on patient care. The ... be a resource for Nebraska patients and a tool ... and referral functionality, video content and resources to understand ...
(Date:3/5/2015)... March 05, 2015 HomeCEUConnection.com ... March with extra savings on their nutrition ... of health and nutrition, HomeCEUConnection.com is offering ... the promo code, NUTRITION2015 . , ... , HomeCEUConnection.com provides high-quality continuing education ...
(Date:3/5/2015)... On March 2, 2015, NBC News posted ... Rise, Plastic Surgeons Say,” that comments on the 2014 ... Plastic Surgery and the American Society of ... doubling of surgical butt augmentations performed in 2014. According ... this increase can be attributed to the social impact ...
(Date:3/5/2015)... In honor of National Drug Facts Week, ... and alcohol abuse in schools and communities across America, ... information on some of the dangers and statistics involved ... Institute on Drug Abuse, this annual promotion of the ... illusions that teens and young adults get from television, ...
(Date:3/5/2015)... MS (PRWEB) March 05, 2015 At ... Basics and Beyond,” leaders in addiction treatment met today ... updates in best clinical practices. Among the numerous respected ... , who will address the role that pain medications ... and new evidence-based treatment options. , "It is hard ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3
... can learn much from each other in regard ... wrong-site surgeries, HARRISBURG, Pa., Jan. 10 ... decreased during 2007, some,facilities continue to report wrong-site ... protocols implemented by other Pennsylvania,facilities that have been ...
... Prepares to Release Alarming New HIV Rates; Governor ... 10 AIDS Healthcare,Foundation (AHF) today urged California ... of proposed budget cuts in AIDS services,that will ... for,Californians living with HIV/AIDS as he seeks to ...
... for "The Grove Circle," Honoring Planned Gift Donors,Reflects Shared ... - Andrew S. Grove,co-founder of technology giant Intel and ... Research, announced his intent to bequeath a,portion of his ... Fox Foundation.,Mr. Grove,s gift will establish The Grove Circle, ...
... can alter timetable , , THURSDAY, Jan. 10 (HealthDay News) -- ... a half years following their diagnosis, new British research shows. ... life expectancy, according to the report in the Jan. 11 ... Common socioeconomic influences, such as marital status, social class and ...
... January 9, 2008 In a study published ... from the University of Aberdeen report that the ... and praised as "the first and,only representative of ... fact similar,to other existing compounds, and is beneficial ...
... Animal study shows preconditioning cardiac cells helps organ better tolerate ... -- Just as daily runs can prepare you to survive ... spells could condition cardiac cells to better withstand the damage ... University of Cincinnati suggests. , Ultimately, if validated in humans, ...
Cached Medicine News:Health News:Patient Safety Authority Visits Facilities for Information on Wrong-Site Surgery 2Health News:Patient Safety Authority Visits Facilities for Information on Wrong-Site Surgery 3Health News:Patient Safety Authority Visits Facilities for Information on Wrong-Site Surgery 4Health News:AHF to Schwarzenegger: 'AIDS Cuts Are Deadly' 2Health News:AHF to Schwarzenegger: 'AIDS Cuts Are Deadly' 3Health News:Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation 2Health News:Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation 3Health News:Dementia Diagnosis Typically Means Death Within Five Years 2Health News:Memantine and Alzheimer's disease 2Health News:Memantine and Alzheimer's disease 3Health News:Priming Heart Before an Attack Could Limit Damage 2Health News:Priming Heart Before an Attack Could Limit Damage 3
Blunt tlpped forceps wlth smooth jaws that have been diamond dusted for enhanced grasping. Excellent for grasping of immature membranes....
Blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
Pic forceps design that is slightly curved; tips have special "surface treatment" for enhanced manipulation of the retina....
Blunt tipped forceps with very small grasping platforms on each tip. For grasping very fine membranes or grasping membranes adherent to the retinal surface....
Medicine Products: